Tavros Therapeutics

A precision oncology platform company discovering novel targets and biomarkers in areas of high unmet clinical need.

Tavros is also leveraging its proprietary platform and map of useful synthetic lethal relationships to build a pipeline of small-molecule drug candidates. Strategic partnerships with Zentalis Pharmaceuticals, OpenBench, and Vividion Therapeutics have validated the platform and expanded the company’s clinical impact.